EP1507513A1 - Preparation ophthalmologique en gel formant des gouttes et contenant de la diclofenamide et du timolol - Google Patents

Preparation ophthalmologique en gel formant des gouttes et contenant de la diclofenamide et du timolol

Info

Publication number
EP1507513A1
EP1507513A1 EP02758204A EP02758204A EP1507513A1 EP 1507513 A1 EP1507513 A1 EP 1507513A1 EP 02758204 A EP02758204 A EP 02758204A EP 02758204 A EP02758204 A EP 02758204A EP 1507513 A1 EP1507513 A1 EP 1507513A1
Authority
EP
European Patent Office
Prior art keywords
weight
composition according
ophthalmic composition
diclofenamide
timolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02758204A
Other languages
German (de)
English (en)
Inventor
Günther Bellmann
Gudrun Claus-Herz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Gerhard Mann Chem Pharm Fabrik GmbH
Original Assignee
Dr Gerhard Mann Chem Pharm Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Gerhard Mann Chem Pharm Fabrik GmbH filed Critical Dr Gerhard Mann Chem Pharm Fabrik GmbH
Publication of EP1507513A1 publication Critical patent/EP1507513A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Definitions

  • the present invention relates to an ophthalmic drip gel preparation containing diclofenamide in its free form and timolol.
  • the present invention further relates to the use of a dripable gel preparation containing the free form of diclofenamide and timolol, for the treatment of ocular hypertension and ocular circulatory disorders and for the therapy of primary and secondary open-angle glaucoma.
  • Glaucoma is a degenerative disease of the eye, which is characterized in that the optic nerve is damaged by increased intraocular pressure and, as a result, it can lead to defects in the visual field. Without treatment, glaucoma can lead to blindness. Recently, a disruption of the microcirculation in ocular vessels as well as the increased ocular intraocular pressure, which is classically diagnosed as a typical glaucoma symptom, is suspected as one of the reasons for the occurrence of glaucoma.
  • a number of active substances are known in the prior art with which the intraocular pressure can be reduced and thus the glaucoma can be treated. These include, for example, beta-receptor blockers such as timolol and carbonic anhydrase inhibitors such as diclofenamide, dorzolamide, brinzolamide and the prostaglandin derivative latanoprost.
  • beta-receptor blockers such as timolol
  • carbonic anhydrase inhibitors such as diclofenamide, dorzolamide, brinzolamide and the prostaglandin derivative latanoprost.
  • diclofenamide INN: 4,5-dichlorobenzene-1,3-disulfonamide
  • European patent EP 033 042 B1 teaches the use of various carbonic anhydrase inhibitors in the form of their alkali metal salts for the production of ophthalmic inserts and solutions.
  • the use of the carbonic anhydrase inhibitors in the form of their alkali metal salts ensures that the active ingredients are in dissolved form in the ophthalmic preparations. This is necessary because, according to the teaching of this patent, the topical application of the free form of the diclofenamide does not bring about a reduction in the intraocular pressure.
  • European patent 014 642 B1 teaches the use of carbonic anhydrase inhibitors in the form of their alkali metal salts, and of timolol for the production of ophthalmic inserts and solutions for topical use.
  • the carbonic anhydrase inhibitors listed also include diclofenamide. It is also expressly referred to in this patent specification that the carbonic anhydrase inhibitors must be in the form of their alkali metal salts in order to be soluble.
  • the use of the free acid form of the diclofenamide with / or without timolol is said not to make sense for the reasons mentioned above.
  • the use of ophthalmic solutions which contain diclofenamide in the form of a dissolved alkali metal salt is, however, associated with disadvantages in principle.
  • the solutions In order to dissolve the alkali metal salts of diclofenamide, the solutions must have an elevated pH (pH> 8). Solutions with such a pH value lead to serious undesirable effects when the solutions (or inserts) are repeatedly used, as is necessary for glaucoma patients Side effects such as considerable eye irritation or damage to the cornea.
  • Ophthalmic inserts that are placed under the eyelid are known, but are usually perceived as uncomfortable by the patient.
  • the problems with the elevated pH values are of course also retained when using carbonic anhydrase inhibitors in the form of their alkali metal salts.
  • the international patent application WO 01/52812 AI first suggests the use of the free acid form of diclofenamide in the form of a suspension gel for topical application to the eye.
  • the advantage of the suspension gel is that the high viscosity of the gel ensures that the active ingredient stays in the eye for longer. This eliminates the basic disadvantages of solutions such as the rapid washing out of the active substances, the transport of the active substances through the chamber channel into the nose and the absorption of the active substances there through the nasal mucosa are reduced. As a result of the diminished
  • WO 01/52812 A1 showed that the free acid of the diclofenamide, embedded in the suspension gel, is able to lower the intraocular pressure when applied topically to the eye. Because of the use of the free acid of the diclofenamide, the high pH values that are used to dissolve the alkali metal salts of the diclofenamide are no longer necessary. The pH values of the suspension gel are rather in the range from pH 7 to pH 7.5, so that the suspension gel is well tolerated.
  • the present invention has for its object ophthalmic
  • compositions of solution-like character which contain diclofenamide in its free form in combination with timolol and which overcome the known disadvantages of ophthalmic, diclofenamide-containing compositions of the prior art.
  • it is an object of the present invention to provide solution-like ophthalmic To provide compositions containing diclofenamide in its free form, the ophthalmic composition being suitable for topical application, and the solution-like composition combining the advantages of suspension gels and the advantages of solutions.
  • solution-like ophthalmic compositions containing diclofenamide in its free form which ophthalmic compositions are said to be able to reduce intraocular pressure when used topically in glaucoma patients.
  • Another object of the present invention is to provide solution-like ophthalmic compositions which contain diclofenamide in its free form, the diclofenamide essentially not settling even after a long storage period.
  • the present invention achieves the above-mentioned objects by providing an ophthalmic composition for glaucoma treatment in the form of a drippable gel preparation, comprising the free form of the diclofenamide, timolol, gel former, agents for adjusting the pH, water and, if appropriate, other conventional additives.
  • a dripable gel preparation is understood to mean that the ophthalmic preparation according to the invention is so flowable that it can be dripped out of the storage container without any problems, if appropriate using light pressure.
  • Intraocular pressure is suitable for glaucoma patients, since the combination of the two active ingredients results in a greater reduction in intraocular pressure than would be the case with one active ingredient alone.
  • the intraocular pressure-lowering effect of both active ingredients is also synergistic, i. H.
  • the effect of the combination of the two active substances on the lowering of the eye pressure shows a higher degree than would be expected from the addition of the values for the individual active substances.
  • diclofenamide is used in its free form in these preparations eliminates the increased pH values that occur when the alkali metal salts of diclofenamide are dissolved.
  • the pH values of the preparations according to the invention range between 6.5 to 7.7, preferably between 7 to 7.5, particularly preferably around 7.2 and likewise particularly preferably around 7.3. These pH values ensure that the dripable gel preparations according to the invention do not irritate the eyes.
  • dripable gel preparations according to the invention can be used topically on the eye also eliminates the side effects that occur due to the systemic use of the free acid of diclofenamide.
  • the reduction in viscosity caused by adding the second active ingredient timolol leads to that the dripable gel preparations according to the invention have a viscosity which on the one hand is so low that the preparations are perceived as pleasant and not disturbing by the patient on the eye due to their solution-like properties, on the other hand because of the remaining gel properties one compared to pure solutions, longer residence time of the active substances in the eye and thus higher absorption of the active substances is given to the eye.
  • the transport to and absorption through the nasal mucosa is also reduced and the systemic side effects are reduced accordingly.
  • the active ingredients are not washed out as quickly as in pure solutions via the chamber channel. Therefore, a larger amount of active ingredient is absorbed in the eye.
  • the preparations also contain two active ingredients which act synergistically, the dripable gel preparations according to the invention, which contain diclofenamide in the free form and timolol, are ideally suited to lower the intraocular pressure in glaucoma patients when administered topically. They thus ideally agree on the properties of ophthalmic solutions and ophthalmic suspension gels.
  • the ophthalmic dripable gel preparations according to the invention also have the advantage that although they have a comparatively low viscosity and diclofenamide is used in the free form, there is no significant sedimentation of the diclofenamide.
  • This physical effect which is caused by the addition of timolol and is also not to be expected, has the result that the dripable gel preparations according to the invention do not have to be shaken or only with little effort before use.
  • just bringing the container which contains the dripable gel preparation according to the invention to the eye is sufficient to stir up residues of free diclofenamide which may have settled on standing for a long time.
  • vigorous shaking of the dripable gel preparations according to the invention is not necessary. So that is ensures that patients who forget to shake will still introduce effective solutions into the eye area.
  • ophthalmic compositions containing diclofenamide in the free form and timolol as drippable gel preparations leads to highly effective and well-tolerated therapeutic agents for the treatment of primary and secondary open-angle glaucoma and ocular hypertension.
  • the preparations according to the invention are also able to reduce disorders of the ocular microcirculation, as are suspected to be another cause of glaucoma.
  • the dripable gel preparations according to the invention have a viscosity between 2 to 4000 mPa-s (millipascal seconds), between 5 to 2500 mPa-s, preferably between 10 to 2000 mPa-s and particularly preferably between 12 to 100 mPa-s, and more preferably between 15 to 100 mPa-s.
  • the viscosity of the dripable gel composition according to the invention is preferably adjusted such that the contact time on the eye is at least 5 min (minutes), at least 15 min, preferably at least 30 min, likewise preferably at least 60 min, further preferably at least 90 min, particularly preferably at least 2 h ( Hours), most preferably at least 4 hours and also most preferably at least 6 to 8 hours.
  • the contact time is understood as the period of time measured from the application of the dripable gel preparation according to the invention to the point in time from which the preparation has been completely washed away from the eye together with tear fluid.
  • the person skilled in the art knows how the contact times of drippable gel preparations can be determined.
  • One possibility is e.g. B. mixing a Carbopol-containing gel with fluorescein. The gel is placed in the conjunctival sac and under the reflected light microscope in the case of slit illumination, the fluorescence of the deposited, marked gel is then considered.
  • the active substance content of the suspension gels according to the invention is from 0.1 to 10% by weight, preferably from 0.1 to 5% by weight, more preferably from 0.5 to 5% by weight, more preferably from 2 to 5%, based on diclofenamide % And most preferably between 3 and 5% by weight of the free acid of the diclofenamide.
  • the active substance content of the dripable gel preparations according to the invention is between 0.1 to 1.5% by weight, preferably between 0.2 to 1% by weight, more preferably between 0.25 and 0.75% by weight. % and most preferably between 0.25 and 0.5% by weight. If timolol is used as a salt, the quantities must be adjusted accordingly.
  • the compatibility of the gel formulation according to the invention is very good even over a longer administration period, i.e. there are usually no undesirable side effects on the eye, e.g. Burning and itching.
  • weights are always based on the total composition of the dripable gel composition according to the invention.
  • the free form of the diclofenamide usually has to be micronized. This micronization takes place in accordance with the process customary in the prior art, e.g. by grinding in different types of grinders, grinding and sieving.
  • micronized particles for use in ophthalmic compositions according to the invention preferably have particle sizes of less than 90 ⁇ m, preferably less than 50 ⁇ m, particularly preferably less than 25 ⁇ m.
  • Timolol can be used in the form of the free base, but also in the form of its pharmaceutically usable and equivalent derivatives, salts and the like. When speaking of timolol, this particularly preferably includes the hydrogen maleate salt of timolol in addition to the base.
  • the micronized diclofenamide is preferably sterilized before further processing to form the dripable gel.
  • all polymer compounds suitable for the preparation of stable suspension gels can be used as gel formers.
  • the gelling agent is selected from the group consisting of polyacrylic acid, cellulose ether, polyvinyl alcohol and polysaccharides. These can be either synthetic or natural in origin.
  • hydrogels based on polyacrylic acid and / or cellulose ether are particularly preferred. Are particularly preferred
  • Polyacrylic acid gels in particular based on carbomers of the Carbopol® type, commercially available from B.F. Goodrich. It is particularly preferred to use Carbopol 980 NF as a gel former in dripable gel preparations according to the invention.
  • polyacrylic acid gels such as Carbopol, in particular Carbopol 980 NF, with a content of> 0 to 10% by weight, preferably 0.01 to 5% by weight, more preferably 0.05 to 1% by weight. -%, more preferably 0.1 to 0.5% by weight and most preferably 0.2 to 0.4% by weight.
  • the ophthalmic compositions according to the invention can be preserved by adding a preservative.
  • a preservative All substances which are suitable for use on the eye and are well known to the person skilled in the art can be used as preservatives are used, for example benzyl alcohol, benzalkonium chloride or other quaternary ammonium compounds, chlorhexidine diacetate or digluconate, thiomersal etc.
  • benzododecinium salts in particular benzododecinium chloride, is particularly preferred.
  • Benzododecinium chloride is preferably present with a content of 0.003 to 0.05% by weight, preferably 0.01% by weight.
  • Sorbitol is preferably used as a further additive in the compositions according to the invention.
  • sorbitol is present in a content of 0 to 10% by weight, preferably 2 to 8% by weight, particularly preferably 3 to 6% by weight and most preferably between 3.5 and Contain 4.5 wt .-%.
  • sorbitol e.g. glycerol
  • mannitol e.g. glycerol
  • dextrose e.g. glycerol
  • Mineral acids and bases are preferably used to adjust the pH of the dripable gel preparations according to the invention.
  • the use of sodium hydroxide and / or hydrochloric acid is particularly preferred.
  • the pH of the ophthalmic composition according to the invention is preferably between pH 6.5 and pH 7.7, preferably between pH 7.0 and pH 7.5, and most preferably between pH 7.2 and pH 7.3.
  • the dripable gel preparations according to the invention are produced by the customary methods of the prior art.
  • the so-called base gel the matrix
  • the base gel is sterile and already has the desired low viscosity.
  • the micronized active ingredient diclofenamide is sterilized and added to this sterile suspension gel matrix. This is followed by a completely uniform distribution of the suspended diclofenamide particles.
  • Carbomer (Carbopol 980 NF) 0.2 0.2 0.2 0.4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition ophthalmologique se présentant sous forme de préparation en gel formant des gouttes et contenant de la diclofenamide se présentant sous sa forme libre et du timolol. L'invention concerne également l'utilisation de telles préparations en gel formant des gouttes pour traiter l'hypertension oculaire et les glaucomes à angle ouvert primaires et secondaires.
EP02758204A 2002-05-24 2002-05-24 Preparation ophthalmologique en gel formant des gouttes et contenant de la diclofenamide et du timolol Withdrawn EP1507513A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/005738 WO2003099258A1 (fr) 2002-05-24 2002-05-24 Preparation ophthalmologique en gel formant des gouttes et contenant de la diclofenamide et du timolol

Publications (1)

Publication Number Publication Date
EP1507513A1 true EP1507513A1 (fr) 2005-02-23

Family

ID=29558277

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02758204A Withdrawn EP1507513A1 (fr) 2002-05-24 2002-05-24 Preparation ophthalmologique en gel formant des gouttes et contenant de la diclofenamide et du timolol

Country Status (4)

Country Link
EP (1) EP1507513A1 (fr)
AU (1) AU2002325220A1 (fr)
CA (1) CA2481394A1 (fr)
WO (1) WO2003099258A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL168603A (en) * 2005-05-16 2011-05-31 Resdevco Res And Dev Co Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells
US10183076B2 (en) 2005-05-16 2019-01-22 Resdevco Research And Development Co. L Topical compositions for treatment of irritation of mucous membranes
CN102869345B (zh) 2010-03-17 2015-02-11 诺瓦利克有限责任公司 用于治疗眼内压增高的药物组合物
AU2013211645B2 (en) 2012-01-23 2017-06-15 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
EP3181119B1 (fr) 2012-09-12 2019-07-10 Novaliq GmbH Compositions d'alkane semifluoré pour utilisation dans le traitement de la secheresse oculaire
PT3355990T (pt) 2015-09-30 2019-09-11 Novaliq Gmbh Compostos semifluorados e as suas composições
JP6869336B2 (ja) 2016-09-23 2021-05-12 ノバリック ゲーエムベーハー シクロスポリンを含む眼科用組成物
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
WO2019166631A1 (fr) 2018-03-02 2019-09-06 Novaliq Gmbh Compositions pharmaceutiques contenant du nébivolol
JP7496778B2 (ja) * 2018-03-28 2024-06-07 ノバリック ゲーエムベーハー チモロールを含む医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ192673A (en) * 1979-02-02 1984-07-06 Merck & Co Inc Ophthalmic compositions for lowering intraocular pressure
DE3068986D1 (en) * 1980-01-28 1984-09-27 Merck & Co Inc Ophthalmic inserts for lowering intraocular pressure comprising carbonic anhydrase inhibitors
US4678855A (en) * 1985-10-09 1987-07-07 Merck & Co., Inc. Substituted benzenesulfonamides
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
PT1251826E (pt) * 2000-01-20 2003-12-31 Mann Gerhard Chem Pharm Fab Gel de suspensao de ciclofenamida

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03099258A1 *

Also Published As

Publication number Publication date
AU2002325220A1 (en) 2003-12-12
CA2481394A1 (fr) 2003-12-04
WO2003099258A1 (fr) 2003-12-04

Similar Documents

Publication Publication Date Title
EP1455803B2 (fr) Utilisation du panthenol et/ou d'acide pantothénique ou d'acide hyaluronique et/ou de hyaluronate pour la manufacture d'une composition pharmaceutique pour une utilisation ophtalmologique
DE69634414T2 (de) Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
DE60006262T2 (de) Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
DE60118859T2 (de) Pharmazeutische Zusammensetzung enthaltend Trehalose zur ophthalmischen Verwendung
EP0801948B1 (fr) Composition ophtalmique à temps de sejour prolongé
EP1948131B3 (fr) Composition pharmaceutique exempte de dexpanthenol, d'ions de calcium et de phosphate, utilisation de chelateurs du calcium et d'un regulateur de viscosite acceptable sur le plan ophtalmique
WO1988010121A1 (fr) Emploi d'un medicament pour traiter l'oeil et support approprie
CH629385A5 (de) Arzneimitteltraeger zum aufbringen einer kompatiblen, pharmakologisch aktiven, chemischen substanz auf eine schleimhaut.
EP1453523B1 (fr) Agent ophtalmique contenant de l'heparine
DE2649095A1 (de) Fuer kuenstliche traenen geeignete loesung fuer die ophthalmologische anwendung
CH685099A5 (de) Pharmazeutisches Präparat für die intranasale Anwendung.
EP1532986B1 (fr) Composition pharmaceutique pour le traitement de la rhinite
EP0773022A2 (fr) Composition pharmaceutique pour le traitement de la rhinite, contenant un sympathomimétique et du pantothenol et/ou l'acide pantothénique
EP1507513A1 (fr) Preparation ophthalmologique en gel formant des gouttes et contenant de la diclofenamide et du timolol
DE60013126T2 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
DE60205913T2 (de) Ophthalmische zubereitung mit n-acetylcystein zur behandlung trockener augen
DE3440352A1 (de) Dry-eye-packung
EP3606505A1 (fr) Composition pour application nasale
EP0585896B1 (fr) Médicament pour l'application topique à l'oeil pour le traitement de la tension intraoculaire élevée
DE60132325T2 (de) Ophthalmische lösung
DE69819900T2 (de) Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil
EP1251826B1 (fr) Gel suspension de diclofenamide
WO2010031096A1 (fr) Composition à action antimicrobienne et antivirale
DE10360425A1 (de) Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung
EP0529499A1 (fr) Compositions à utilisation topique pour l'application au nez ou aux yeux à base d'antagonistes de bradykinine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061201